Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Treatment of primary dysmenorrhea in adult women

INTRODUCTION

Primary dysmenorrhea refers to the presence of recurrent, crampy, lower abdominal pain occurring during menses and in the absence of demonstrable disease. The management of women with primary dysmenorrhea will be reviewed here. The pathogenesis, clinical manifestations, and diagnosis of primary dysmenorrhea are discussed separately. (See "Primary dysmenorrhea in adult women: Clinical features and diagnosis".)

TREATMENT OVERVIEW

Goal — The goal of treatment is to provide adequate relief of pain. At a minimum, pain relief should be sufficient to allow the woman to perform most, if not all, of her usual activities.

General approach — Treatment of primary dysmenorrhea can be initiated empirically. Laboratory tests, imaging studies, and/or laparoscopy are not required to definitively exclude causes of secondary dysmenorrhea when a detailed history and physical examination strongly support the diagnosis. (See "Primary dysmenorrhea in adult women: Clinical features and diagnosis", section on 'Diagnosis' and "Primary dysmenorrhea in adult women: Clinical features and diagnosis", section on 'Diagnostic evaluation'.)

General measures for management include patient education and reassurance. Treatment is supportive and should be guided by individual needs, as the severity of pain and degree of limitation of activity vary widely among women with dysmenorrhea (table 1). The initial approach includes a discussion of nonpharmacologic interventions that can be helpful, such as application of a heat pack to the lower abdomen, exercise, and relaxation techniques. First-line pharmacologic therapy includes nonsteroidal anti-inflammatory drugs (NSAIDs) and/or estrogen-progestin contraceptives (cyclic, long-cycle, or continuous), depending on the clinical needs of the patient. For women with primary dysmenorrhea desiring contraception, estrogen-progestin contraceptives are a logical choice. For women who prefer not to use hormonal treatment, NSAIDs are a logical choice. However, some women may need both types of treatment. (See 'Drug therapy' below.)

Women who do not achieve adequate pain relief after three months of treatment with NSAIDs and hormonal contraceptives may have secondary dysmenorrhea due to endometriosis or other conditions. Options for these women include diagnostic laparoscopy or empiric GnRH agonist therapy. Intrauterine progestin delivery systems (levonorgestrel intrauterine system) have demonstrated some efficacy in women with dysmenorrhea secondary to either proven or suspected endometriosis. (See 'Management of treatment failure' below.)

                          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Oct 2014. | This topic last updated: Feb 12, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Akin MD, Weingand KW, Hengehold DA, et al. Continuous low-level topical heat in the treatment of dysmenorrhea. Obstet Gynecol 2001; 97:343.
  2. Akin M, Price W, Rodriguez G Jr, et al. Continuous, low-level, topical heat wrap therapy as compared to acetaminophen for primary dysmenorrhea. J Reprod Med 2004; 49:739.
  3. Israel RG, Sutton M, O'Brien KF. Effects of aerobic training on primary dysmenorrhea symptomatology in college females. J Am Coll Health 1985; 33:241.
  4. Brown J, Brown S. Exercise for dysmenorrhoea. Cochrane Database Syst Rev 2010; :CD004142.
  5. Golomb LM, Solidum AA, Warren MP. Primary dysmenorrhea and physical activity. Med Sci Sports Exerc 1998; 30:906.
  6. Rakhshaee Z. Effect of three yoga poses (cobra, cat and fish poses) in women with primary dysmenorrhea: a randomized clinical trial. J Pediatr Adolesc Gynecol 2011; 24:192.
  7. Hatcher RA. Counseling couples about coitus during menstrual flow. Contracept Technol Update 1981; 2:167.
  8. Proctor ML, Murphy PA, Pattison HM, et al. Behavioural interventions for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2007; :CD002248.
  9. Barnard ND, Scialli AR, Hurlock D, Bertron P. Diet and sex-hormone binding globulin, dysmenorrhea, and premenstrual symptoms. Obstet Gynecol 2000; 95:245.
  10. Abdul-Razzak KK, Ayoub NM, Abu-Taleb AA, Obeidat BA. Influence of dietary intake of dairy products on dysmenorrhea. J Obstet Gynaecol Res 2010; 36:377.
  11. Ziaei S, Faghihzadeh S, Sohrabvand F, et al. A randomised placebo-controlled trial to determine the effect of vitamin E in treatment of primary dysmenorrhoea. BJOG 2001; 108:1181.
  12. Ziaei S, Zakeri M, Kazemnejad A. A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhoea. BJOG 2005; 112:466.
  13. Proctor ML, Murphy PA. Herbal and dietary therapies for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2001; :CD002124.
  14. Lasco A, Catalano A, Benvenga S. Improvement of primary dysmenorrhea caused by a single oral dose of vitamin D: results of a randomized, double-blind, placebo-controlled study. Arch Intern Med 2012; 172:366.
  15. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303:1815.
  16. Fedele L, Marchini M, Acaia B, et al. Dynamics and significance of placebo response in primary dysmenorrhea. Pain 1989; 36:43.
  17. Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010; :CD001751.
  18. Owen PR. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed. Am J Obstet Gynecol 1984; 148:96.
  19. Zhang, WY, Li Wan, Po A. Efficacy of minor analgesics in primary dysmenorrhea: a systematic review. Br J Obstet Gynaecol 1998; 105;780.
  20. Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception 2010; 81:185.
  21. Budoff PW. Use of mefenamic acid in the treatment of primary dysmenorrhea. JAMA 1979; 241:2713.
  22. Milsom I, Minic M, Dawood MY, et al. Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: a pooled analysis of five studies. Clin Ther 2002; 24:1384.
  23. Pall M, Fridén BE, Brännström M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum Reprod 2001; 16:1323.
  24. Duffy DM, VandeVoort CA. Maturation and fertilization of nonhuman primate oocytes are compromised by oral administration of a cyclooxygenase-2 inhibitor. Fertil Steril 2011; 95:1256.
  25. Bata MS, Al-Ramahi M, Salhab AS, et al. Delay of ovulation by meloxicam in healthy cycling volunteers: A placebo-controlled, double-blind, crossover study. J Clin Pharmacol 2006; 46:925.
  26. Jesam C, Salvatierra AM, Schwartz JL, Croxatto HB. Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception. Hum Reprod 2010; 25:368.
  27. Uhler ML, Hsu JW, Fisher SG, Zinaman MJ. The effect of nonsteroidal anti-inflammatory drugs on ovulation: a prospective, randomized clinical trial. Fertil Steril 2001; 76:957.
  28. Toppozada, M, El-Abd, M, El-Sokkary, H, El-Rahman, HA. Effect of a prostaglandin inhibitor of human ovulation. Singapore J Obstet Gynecol 1979; 10:42.
  29. Lundström V, Landgren BM, Eneroth P, Johannisson E. The effect of a prostaglandin synthetase inhibitor on the hormonal profile and the endometrium in women. Acta Obstet Gynecol Scand Suppl 1983; 113:77.
  30. Athanasiou S, Bourne TH, Khalid A, et al. Effects of indomethacin on follicular structure, vascularity, and function over the periovulatory period in women. Fertil Steril 1996; 65:556.
  31. Killick S, Elstein M. Pharmacologic production of luteinized unruptured follicles by prostaglandin synthetase inhibitors. Fertil Steril 1987; 47:773.
  32. Norman RJ. Reproductive consequences of COX-2 inhibition. Lancet 2001; 358:1287.
  33. Norman RJ, Wu R. The potential danger of COX-2 inhibitors. Fertil Steril 2004; 81:493.
  34. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev 2009; :CD002120.
  35. Davis AR, Westhoff C, O'Connell K, Gallagher N. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol 2005; 106:97.
  36. Callejo J, Díaz J, Ruiz A, García RM. Effect of a low-dose oral contraceptive containing 20 microg ethinylestradiol and 150 microg desogestrel on dysmenorrhea. Contraception 2003; 68:183.
  37. Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception 2004; 69:469.
  38. Endrikat J, Jaques MA, Mayerhofer M, et al. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995; 52:229.
  39. Hendrix SL, Alexander NJ. Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception 2002; 66:393.
  40. Edelman AB, Gallo MF, Jensen JT, et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; :CD004695.
  41. Machado RB, de Melo NR, Maia H Jr. Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study. Contraception 2010; 81:215.
  42. Roumen FJ. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Contraception 2007; 75:420.
  43. Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001; 285:2347.
  44. Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception 2009; 80:113.
  45. Harel Z, Biro FM, Kollar LM. Depo-Provera in adolescents: effects of early second injection or prior oral contraception. J Adolesc Health 1995; 16:379.
  46. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 2006; 125:9.
  47. Bahamondes L, Petta CA, Fernandes A, Monteiro I. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception 2007; 75:S134.
  48. Lindh I, Milsom I. The influence of intrauterine contraception on the prevalence and severity of dysmenorrhea: a longitudinal population study. Hum Reprod 2013; 28:1953.
  49. Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005; 20:1993.
  50. Bragheto AM, Caserta N, Bahamondes L, Petta CA. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 2007; 76:195.
  51. http://www.prnewswire.com/news-releases/us-fda-approves-bayers-skyla-levonorgestrel-releasing-intrauterine-system-135-mg-for-prevention-of-pregnancy-for-up-to-three-years-186215742.html. (Accessed on May 28, 2013).
  52. Wildemeersch D, Schacht E, Wildemeersch P. Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care 2001; 6:192.
  53. Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000; 5 Suppl 2:21.
  54. Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study. Contraception 2009; 79:29.
  55. Moya RA, Moisa CF, Morales F, et al. Transdermal glyceryl trinitrate in the management of primary dysmenorrhea. Int J Gynaecol Obstet 2000; 69:113.
  56. Facchinetti F, Sgarbi L, Piccinini F, Volpe A. A comparison of glyceryl trinitrate with diclofenac for the treatment of primary dysmenorrhea: an open, randomized, cross-over trial. Gynecol Endocrinol 2002; 16:39.
  57. Morgan PJ, Kung R, Tarshis J. Nitroglycerin as a uterine relaxant: a systematic review. J Obstet Gynaecol Can 2002; 24:403.
  58. Andersson KE, Ulmsten U. Effects of nifedipine on myometrial activity and lower abdominal pain in women with primary dysmenorrhoea. Br J Obstet Gynaecol 1978; 85:142.
  59. Ulmsten U. Calcium blockade as a rapid pharmacological test to evaluate primary dysmenorrhea. Gynecol Obstet Invest 1985; 20:78.
  60. Sandahl B, Ulmsten U, Andersson KE. Trial of the calcium antagonist nifedipine in the treatment of primary dysmenorrhoea. Arch Gynecol 1979; 227:147.
  61. Dmitrovic R, Kunselman AR, Legro RS. Sildenafil citrate in the treatment of pain in primary dysmenorrhea: a randomized controlled trial. Hum Reprod 2013; 28:2958.
  62. Cho SH, Hwang EW. Acupuncture for primary dysmenorrhoea: a systematic review. BJOG 2010; 117:509.
  63. Cho SH, Hwang EW. Acupressure for primary dysmenorrhoea: a systematic review. Complement Ther Med 2010; 18:49.
  64. Proctor ML, Hing W, Johnson TC, Murphy PA. Spinal manipulation for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2006; :CD002119.
  65. Zhu X, Proctor M, Bensoussan A, et al. Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database Syst Rev 2007; :CD005288.
  66. Proctor ML, Smith CA, Farquhar CM, Stones RW. Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea. Cochrane Database Syst Rev 2002; :CD002123.
  67. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 2006; 108:428.
  68. Smith RP, Heltzel JA. Interrelation of analgesia and uterine activity in women with primary dysmenorrhea. A preliminary report. J Reprod Med 1991; 36:260.
  69. Proctor ML, Latthe PM, Farquhar CM, et al. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2005; :CD001896.
  70. Missmer SA, Hankinson SE, Spiegelman D, et al. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol 2004; 160:784.
  71. Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Obstet Gynecol 1999; 93:51.
  72. ACOG Practice Bulletin Number 11. Medical Management of Endometriosis. December 1999.